Literature DB >> 1654439

Cellular ras gene activity is required for full neoplastic transformation by polyomavirus.

L Raptis1, R Marcellus, M J Corbley, A Krook, J Whitfield, S K Anderson, T Haliotis.   

Abstract

To investigate the role of ras gene activity in cellular transformation by polyomavirus, murine C3H10T1/2 cells were rendered ras deficient by transfection with an antisense ras gene construct. Ras deficiency resulted in a partial suppression of the polyomavirus-induced transformed phenotype. The production of viral middle T antigen and its association with pp60c-src, increased membrane-associated protein kinase C activity, and morphological transformation were unaffected by the downregulation of c-ras gene expression. On the other hand, stimulated proliferation, focus formation on confluent monolayers of normal cells, and colony formation in soft agar were all greatly reduced in cells containing reduced p21ras levels. It is concluded that ras gene activity is needed for full cell transformation by polyomavirus.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1654439      PMCID: PMC248998     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  A ras-related gene with transformation suppressor activity.

Authors:  H Kitayama; Y Sugimoto; T Matsuzaki; Y Ikawa; M Noda
Journal:  Cell       Date:  1989-01-13       Impact factor: 41.582

2.  Tyr527 is phosphorylated in pp60c-src: implications for regulation.

Authors:  J A Cooper; K L Gould; C A Cartwright; T Hunter
Journal:  Science       Date:  1986-03-21       Impact factor: 47.728

3.  Protein kinase C promotes the phosphorylation of immunoprecipitated middle T antigen from polyoma-transformed cells.

Authors:  L Raptis; A L Boynton; J F Whitfield
Journal:  Biochem Biophys Res Commun       Date:  1986-05-14       Impact factor: 3.575

4.  Polyomavirus transforms rat F111 and mouse NIH 3T3 cells by different mechanisms.

Authors:  L Raptis; J B Bolen
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

5.  Biological and biochemical properties of human rasH genes mutated at codon 61.

Authors:  C J Der; T Finkel; G M Cooper
Journal:  Cell       Date:  1986-01-17       Impact factor: 41.582

6.  Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells.

Authors:  L S Mulcahy; M R Smith; D W Stacey
Journal:  Nature       Date:  1985 Jan 17-23       Impact factor: 49.962

7.  Scrape-loading of Swiss 3T3 cells with ras protein rapidly activates protein kinase C in the absence of phosphoinositide hydrolysis.

Authors:  J D Morris; B Price; A C Lloyd; A J Self; C J Marshall; A Hall
Journal:  Oncogene       Date:  1989-01       Impact factor: 9.867

8.  Ras interaction with the GTPase-activating protein (GAP).

Authors:  M D Schaber; V M Garsky; D Boylan; W S Hill; E M Scolnick; M S Marshall; I S Sigal; J B Gibbs
Journal:  Proteins       Date:  1989

9.  Mutations around the NG59 lesion indicate an active association of polyoma virus middle-T antigen with pp60c-src is required for cell transformation.

Authors:  S H Cheng; W Markland; A F Markham; A E Smith
Journal:  EMBO J       Date:  1986-02       Impact factor: 11.598

10.  Requirement for c-ras proteins during viral oncogene transformation.

Authors:  M R Smith; S J DeGudicibus; D W Stacey
Journal:  Nature       Date:  1986 Apr 10-16       Impact factor: 49.962

View more
  13 in total

Review 1.  Natural biology of polyomavirus middle T antigen.

Authors:  K A Gottlieb; L P Villarreal
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

2.  A novel 39-kilodalton membrane protein binds GTP in polyomavirus-transformed cells.

Authors:  P H Bauer; T L Benjamin
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

3.  Polyomavirus middle-sized tumor antigen modulates c-Jun phosphorylation and transcriptional activity.

Authors:  S Srinivas; A Schönthal; W Eckhart
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

4.  Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes.

Authors:  Zakaria Y Abd Elmageed; Yijun Yang; Raju Thomas; Manish Ranjan; Debasis Mondal; Krzysztof Moroz; Zhide Fang; Bashir M Rezk; Krishnarao Moparty; Suresh C Sikka; Oliver Sartor; Asim B Abdel-Mageed
Journal:  Stem Cells       Date:  2014-04       Impact factor: 6.277

5.  Transformation and tumorigenic properties of a mutant polyomavirus containing a middle T antigen defective in Shc binding.

Authors:  X Yi; J Peterson; R Freund
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

6.  Targeting the PyMT Oncogene to Diverse Mammary Cell Populations Enhances Tumor Heterogeneity and Generates Rare Breast Cancer Subtypes.

Authors:  Brittni A Smith; Dawne N Shelton; Collin Kieffer; Brett Milash; Jerry Usary; Charles M Perou; Philip S Bernard; Bryan E Welm
Journal:  Genes Cancer       Date:  2012-09

7.  Polyoma middle tumor antigen interacts with SHC protein via the NPTY (Asn-Pro-Thr-Tyr) motif in middle tumor antigen.

Authors:  K S Campbell; E Ogris; B Burke; W Su; K R Auger; B J Druker; B S Schaffhausen; T M Roberts; D C Pallas
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

8.  Amino-terminal regions of polyomavirus middle T antigen are required for interactions with protein phosphatase 2A.

Authors:  G M Glenn; W Eckhart
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

9.  Transformation of enriched mammary cell populations with polyomavirus middle T antigen influences tumor subtype and metastatic potential.

Authors:  Daria Drobysheva; Brittni Alise Smith; Maria McDowell; Katrin P Guillen; Huseyin Atakan Ekiz; Bryan E Welm
Journal:  Breast Cancer Res       Date:  2015-10-01       Impact factor: 6.466

10.  Elp3 links tRNA modification to IRES-dependent translation of LEF1 to sustain metastasis in breast cancer.

Authors:  Sylvain Delaunay; Francesca Rapino; Lars Tharun; Zhaoli Zhou; Lukas Heukamp; Martin Termathe; Kateryna Shostak; Iva Klevernic; Alexandra Florin; Hadrien Desmecht; Christophe J Desmet; Laurent Nguyen; Sebastian A Leidel; Anne E Willis; Reinhard Büttner; Alain Chariot; Pierre Close
Journal:  J Exp Med       Date:  2016-10-10       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.